Market landscape of penicillin for syphilis and rheumatic heart disease, WHO South-East Asia Region Authors: Gereltuya Dorj, Uhjin Kim, Po-Lin Chan, Pradeep Joshi, Abhishek Royal, Karina Razali Published: 2026 ABSTRACT AbstractObjectiveTo assess the market landscape of penicillin formulations used for the treatment of syphilis and rheumatic heart disease in the World Health Organization South-East Asia Region.MethodsWe analysed market data for five essential penicillin formulations across nine countries in the South-East Asia Region using a survey form to collect data on product registration, inclusion in national essential medicines lists, procurement, availability, pricing and demand forecasting.FindingsSubstantial disparities exist in registration status, procurement and pricing across the region. The price of benzathine benzylpenicillin 1.2 million international units (IU) in Timor-Leste was over 23 times higher than in Bangladesh (3.45 United States dollars, US$, versus US$ 0.15), while the price for 2.4 million IU varied by up to 55–fold across the region. Several countries reported supply issues, including shortages of benzathine benzylpenicillin in India, Maldives, Myanmar, Thailand and Timor-Leste; aqueous benzylpenicillin in Sri Lanka during the 2022 economic crisis; and supply disruptions of phenoxymethylpenicillin 250 mg in Maldives and Sri Lanka. Morbidity-based estimates indicated annual regional demand of 171 966 061 vials of benzathine benzylpenicillin 2.4 million IU and 923 053 121 tablets of phenoxymethylpenicillin 250 mg, with corresponding costs of US$ 62 127 441 and US$ 48 005 181, respectively. India has the highest demand of these two formulations.ConclusionDifferences in registration, procurement, pricing and forecasting undermine reliable access to penicillin products in the South-East Asia Region. Stronger regional collaboration, improved forecasting, harmonized regulatory approaches and pooled procurement strategies are needed to secure equitable and sustainable access. Introduction Reliable access to penicillin formulations is crucial for treating congenital syphilis and managing rheumatic heart disease.1,2 Interventions have demonstrated that elimination of mother-to-child transmission of syphilis is attainable when timely diagnosis and treatment are ensured.3 Without treatment, syphilis can lead to stillbirth, neonatal death and congenital infection.4 The World Health Organization (WHO) recommends injectable benzathine benzylpenicillin (hereafter benzathine penicillin G) as the first-line therapy for maternal syphilis and injectable aqueous benzylpenicillin (hereafter penicillin G) for congenital syphilis;1 there are no recommended oral formulations, making reliable access to injectable penicillin essential. For rheumatic heart disease, long-term intramuscular benzathine penicillin G prophylaxis is essential to prevent recurrent rheumatic fever and disease progression, with oral phenoxymethylpenicillin (hereafter penicillin V) recommended only when benzathine penicillin G is not feasible.2 All five key penicillin formulations indicated for the treatment and management of these conditions (benzathine penicillin G 1.2 million international units (IU) and 2.4 million IU, penicillin G 1 million IU and penicillin V 250 mg and 500 mg) are included in the WHO Model list of essential medicines, 24th list.5 Despite these longstanding guidelines recommending penicillin-based regimens, there have been intermittent global penicillin shortages.6 In the WHO South-East Asia Region, access is uneven due to fragmented supply chains, regulatory barriers and weak market incentives.7 Many countries in the region report inconsistent availability, formulation-specific shortages and fragmented procurement systems.6–10 In the South-East Asia Region, syphilis is a significant public health concern. In 2021, an estimated 22 500 pregnant women reported with syphilis infection, leading to 8100 infants with congenital syphilis and 5000 adverse pregnancy outcomes.11 WHO’s triple elimination framework aims to eliminate mother-to-child transmission of human immunodeficiency virus (HIV), syphilis and hepatitis B, but progress across the region is uneven.3 Maldives and Sri Lanka have maintained validated elimination status since 2019, whereas Thailand, which achieved validated elimination in 2016, has reported a rising trend in cases in recent years.12–15 Congenital syphilis data across the region remain limited and national reporting practices vary widely (Table 1). Table 1Country-level burden of syphilis and rheumatic heart disease, WHO South-East Asia Region, 2024–2025Member StatePopulationaSyphilisbRheumatic heart diseasePregnant women testedPositive pregnant womenTreated pregnant womenCongenital casesPrevalence per 100 000cEstimated casesBangladesh172 000 000583 20000NA7561 295 671Bhutan780 00012 000545449c7335 765India1 428 600 00020 678 0008 2717 0551446919 935 030Democratic People’s Republic of Koread26 100 0001 11000NA711187 756Maldives530 0009 00000NA7654 023Myanmar55 200 000627 3004 0773 939NA862466 414Nepal30 900 000136 500915296NA693205 638Sri Lanka21 600 000299 840150136146314 458Thailand71 800 000596 40010 2589 8371 290724518 908Timor-Leste1 400 00037 480311280NA78710 900NA: not available; WHO: World Health Organization.a Estimated population for 2024–2025 from United Nations World Population Prospects 2024.16b Syphilis age-standardized data in 2024.14c Rheumatic heart disease prevalence data.15 d Democratic People’s Republic of Korea was only included in the forecasting analysis for the region, using published data.14,15 Survey data were not submitted for the broader analyses. Country-level burden of syphilis and rheumatic heart disease, WHO South-East Asia Region, 2024–2025 NA: not available; WHO: World Health Organization. a Estimated population for 2024–2025 from United Nations World Population Prospects 2024.16 b Syphilis age-standardized data in 2024.14 c Rheumatic heart disease prevalence data.15 d Democratic People’s Republic of Korea was only included in the forecasting analysis for the region, using published data.14,15 Survey data were not submitted for the broader analyses. Rheumatic heart disease is also a significant public health issue in the region, driven by socioeconomic inequities including poverty, overcrowding and constrained treatment access.2 In 2021, the highest rheumatic heart disease prevalence in the region was reported in Myanmar (862 cases per 100 000 population), Timor-Leste (787 cases per 100 000 population) and Maldives (765 cases per 100 000 population); India, the country with the highest disease burden, reported prevalence of 691 cases per 100 000 population.15 Successful treatment and management of syphilis and rheumatic heart disease depend on the reliable availability of penicillin products, which come from the same penicillin supply chain. However, region-specific evidence on how penicillin registration, its inclusion on national essential medicines lists, procurement, pricing and forecasting interact to shape access remains limited.7,17 Here, we comprehensively assess the penicillin market functionality, formulation-specific vulnerabilities and integrated procurement and forecasting needs across the Member States of the WHO South-East Asia Region. Methods Study design This cross-sectional observational study collected data using a structured survey (available from online repository),18 which we distributed to national regulatory, procurement and health programme authorities across 10 Member States in the region between 1 February 2025 and 30 May 2025. Nine countries responded: Bangladesh, Bhutan, India, Maldives, Myanmar, Nepal, Sri Lanka, Thailand and Timor-Leste. For data on shortages, availability and quantification practices we used a reporting period of the previous three years (2022 to 2025) and for cost data for penicillin we used costs from the most recent and available reporting period. Data collection The survey focused on the five essential penicillin formulations recommended by WHO for the treatment of syphilis and management of rheumatic heart disease:5 benzathine penicillin G 1.2 million IU and 2.4 million IU; penicillin G 1 million IU; penicillin V 250 mg and 500 mg. For each formulation, we collected market and policy data across seven dimensions: (i) product registration status; (ii) inclusion in national essential medicines lists; (iii) procurement mechanisms and requirements; (iv) product availability and shortage history; (v) indications and inclusion in national guidelines; (vi) unit prices; and (vii) demand quantification and surveillance practices. We collected available morbidity and cost data to calculate demand forecasts for penicillin formulations across the region. We obtained the morbidity data from official sources, including national statistical offices, WHO’s Global Health Observatory and the Institute for Health Metrics and Evaluation’s global burden of disease results; 14,15 we obtained cost data from health ministries. Definitions To ensure comparability across countries, we applied the following operational definitions: (i) availability is the confirmed presence of a product within the national public-sector supply chain during the preceding three years; (ii) shortages refer to the inability to meet routine programmatic demand due to constraints in procurement, manufacturing or distribution, as reflected in country-reported routine supply and stock-out events; (iii) sufficiency is the absence of reported stock-outs within a three-year period. We classified procurement mechanisms by purchasing authority level: centralized (medicines purchased through a national-level authority); decentralized (purchasing at sub-national or facility level); and mixed (combining centralized procurement with supplementary mechanisms such as sub-national purchasing or external supply channels). Analytic approach Market-level analyses We used a mixed-method descriptive approach, synthesizing the survey data on registration, national essential medicines list inclusion, procurement, availability and shortage history, indications and national guidelines through structured tabular extraction and narrative summaries. We tabulated unit price data (most recent procurement cycle, 2024–2025), summarized demand-related data across countries and formulations and conducted price comparisons in R (R Foundation, Vienna, Austria). Formulation-level analyses We analysed each formulation separately for demand forecasting, pricing, regulatory assessment and clinical use in line with WHO dosing recommendations and country-specific procurement and reporting practices.1,2 We did not assume operational substitution between vial strengths (e.g. using multiple 1.2 million IU vials in place of a 2.4 million IU vial), as differences in registered strength, procurement systems, dosing practices and pragmatic use may limit interchangeability in practice. Demand forecasting analysis We used a combined approach for demand forecasting to enable a comprehensive estimate of penicillin needs for maternal syphilis, congenital syphilis and rheumatic heart disease across the region (Table 2), combining disease burden estimates with WHO-recommended treatment regimens.1,2 Table 2Estimated annual demand of penicillin for syphilis and rheumatic heart disease, WHO South-East Asia Region ConditionPenicillin formulation (strength)DosageEstimated annual need per caseCalculation assumptionsSyphilis in pregnant womenBenzathine penicillin G (2.4 million IU)1–3 doses depending on stage2 doses Programmes typically plan for 2 dosesaCongenital syphilisPenicillin G (1 million IU)50 000 IU/kg per intramuscular or intravenous dose every 12h for 7 days, then every 8h for 3 days23 doses14 doses (days 1–7) plus 9 doses (days 8–10), 23 doses total for 10 daysRheumatic heart disease in adultsBenzathine penicillin G (2.4 million IU)1 intramuscular dose every 3 weeks17 doses per yearBased on 52 weeks in 3-week intervalRheumatic heart disease in adults Penicillin V (250 mg) 250 mg oral dose twice daily730 tablets per year2 tablets per day for 365 daysRheumatic heart disease in childrenPenicillin V (250 mg) 250 mg oral dose once daily365 tablets per year1 tablet per day for 365 daysIU: international units; WHO: World Health Organization.a Syphilis calculations assume a mix of early and late syphilis.Notes: Regimens, dosage and calculation assumptions are based on WHO-recommended treatment regimens.1,2 Benzathine penicillin G and penicillin G are injectable formulations. Estimated annual demand of penicillin for syphilis and rheumatic heart disease, WHO South-East Asia Region IU: international units; WHO: World Health Organization. a Syphilis calculations assume a mix of early and late syphilis. Notes: Regimens, dosage and calculation assumptions are based on WHO-recommended treatment regimens.1,2 Benzathine penicillin G and penicillin G are injectable formulations. For maternal syphilis, we calculated penicillin demand using antenatal care coverage and syphilis positivity rates, assuming two doses of benzathine penicillin G 2.4 million IU per case. We estimated penicillin demand for congenital syphilis using WHO-recommended weight-based neonatal dosing of penicillin G (50 000 IU per kg per dose every 12 hours for the first 7 days, then every 8 hours for the next 3 days)1 and converted this to vial-equivalent demand based on the commonly procured 1 million IU vial strength using an average daily requirement of 0.5 million IU. For rheumatic heart disease, we applied prevalence estimates to calculate annual prophylaxis needs, assuming 17.3 doses of benzathine penicillin G 2.4 million IU or 730 tablets of penicillin V 250 mg per adult patient.2 We defined paediatric rheumatic heart disease dosing assumptions but excluded them from the analysis due to insufficient age-disaggregated data. We used Institute for Health Metrics Evaluation estimates (2021) for rheumatic heart disease and data from the WHO Global Health Observatory for syphilis.14,19,20 We reviewed all data submitted by the nine countries for internal consistency, and cross-checked unclear or implausible values with country focal points and supporting documentation where possible. We treated unresolved values as missing, with no imputation performed. Results Registration and medicines list status Product registration and inclusion in the national essential medicine list of the five penicillin formulations vary across the nine countries. Benzathine penicillin G 1.2 million IU is registered in all countries except Timor-Leste and is included in seven national essential medicines lists, with expedited or waived access in Bhutan, Maldives, Thailand and Timor-Leste. Benzathine penicillin G 2.4 million IU is registered in five countries, all nine include it on their national essential medicines lists, with prioritization in Bhutan and Thailand. Penicillin G is also broadly registered (5/9 countries) and included in some national essential medicines lists (4/9 countries), with prioritization in Bhutan and Maldives. Penicillin V 250 mg is similarly widely registered (8/9 countries) and included in multiple national essential medicines lists (8/9 countries), with Bhutan offering priority access. Penicillin V 500 mg shows minimal registration (4/9 countries) and limited national essential medicines list inclusion (4/9 countries) across the region (Table 3). Table 3Penicillin product registration and inclusion status in national essential medicines lists, WHO South-East Asia Region, 2025Member StateBenzathine penicillin G1.2 million IUBenzathine penicillin G 2.4 million IUPenicillin G 1 million IUPenicillin V 250 mgPenicillin V 500 mgRegistrationIn national essential medicines listRegistrationIn national essential medicines listRegistrationIn national essential medicines listRegistrationIn national essential medicines listRegistrationIn national essential medicines listBangladeshYesYesYesYesYesNoYesYesYesYesBhutanYesNoYesYesNoNoYesYesNoNoIndiaYesYesYesYesYesaYesaYesYesYesNoMaldivesYesYesYesYesNoNoYesYesYesYesMyanmarYesNoYesYesYesNoYesYesYesYesNepalYesYesNoYesNoYesYesYesNoNoSri LankaYesYesNoNoYesNoYesNoNoNoThailandYesYesNoYesYesYesYesYesNoYesTimor-LesteNoYesNoYesNoYesNoYesNoNoIU: international units; WHO: World Health Organization.a Penicillin G 0.5 million IU is registered and included in the national essential medicines list in India instead of 1 million IU. Penicillin product registration and inclusion status in national essential medicines lists, WHO South-East Asia Region, 2025 IU: international units; WHO: World Health Organization. a Penicillin G 0.5 million IU is registered and included in the national essential medicines list in India instead of 1 million IU. Manufacturing and patent status Manufacturing capacity for penicillin formulations varies across the region (Table 4). Benzathine penicillin G 1.2 million IU is manufactured in Bangladesh, India, Nepal and Sri Lanka, while the 2.4 million IU formulation is manufactured in Bangladesh and India. Penicillin G is manufactured in India, Sri Lanka and Thailand. Production of penicillin V 250 mg is similarly widespread, with local manufacturing reported in five countries. Penicillin V 500 mg is manufactured exclusively in India. None of the penicillin formulations are protected by patents. Table 4Local manufacture of penicillin products used for syphilis and rheumatic heart disease, WHO South-East Asia Region, 2025a Member StateBenzathine penicillin G 1.2 million IUBenzathine penicillin G 2.4 million IUPenicillin GPenicillin V 250 mgPenicillin V 500 mgBangladeshSquareSquareNo local manufacturerNo local manufacturerNo local manufacturerBhutanNo local manufacturerNo local manufacturerNo local manufacturerNo local manufacturerNo local manufacturerIndiaKarnataka Antibiotics & Pharmaceuticals Limited Karnataka Antibiotics & Pharmaceuticals Limited Jolly Pharmacy; Karnataka Antibiotics & Pharmaceuticals Limited Hindustan Antibiotics LimitedHindustan Antibiotics LimitedMaldivesNo local manufacturerNo local manufacturerNo local manufacturerNo local manufacturerNo local manufacturerMyanmarNo local manufacturerNo local manufacturerNo local manufacturerMyanmar Pharmaceutical Industrial EnterpriseNo local manufacturerNepalNational Health CareNo local manufacturerNo local manufacturerNepal Pharmaceutical Laboratories Pvt.LtdNo local manufacturerSri LankaNavestaNo local manufacturerNavestaState Pharmaceuticals Manufacturing CorporationNo local manufacturerThailandNo local manufacturerNo local manufacturerGeneral Drugs House Co., LtdMedicpharma Co., LtdNo local manufacturerTimor-LesteNo local manufacturerNo local manufacturerNo local manufacturerNo local manufacturerNo local manufacturerIU: international units; WHO: World Health Organization.a None of the five penicillin products listed are patented in the country of manufacture. Local manufacture of penicillin products used for syphilis and rheumatic heart disease, WHO South-East Asia Region, 2025a IU: international units; WHO: World Health Organization. a None of the five penicillin products listed are patented in the country of manufacture. Procurement and donation mechanism Procurement mechanisms across the region are diverse and external donation support remains limited (Table 5). Benzathine penicillin G 1.2 million IU is procured in most countries through either centralized or mixed systems, with mixed approaches in Bangladesh, Bhutan and Thailand and fully centralized procurement in Maldives and Sri Lanka. Only Bangladesh reported donations of benzathine penicillin G 1.2 million IU, received through targeted programmes for syphilis and rheumatic heart disease. Table 5Procurement system and donation status of penicillin products, WHO South-East Asia, 2022–2024Member StateBenzathine penicillin G 1.2 million IUBenzathine penicillin G 2.4 million IUPenicillin GPenicillin V 250 mgPenicillin V 500 mgProcurement systemDonation statusProcurement systemDonation statusProcurement systemDonation statusProcurement systemDonation statusProcurement systemDonation statusBangladeshMixedRare, targeted donations; predominantly self-procuredNot procuredNo donationNot procuredNo donationProcured only in private sectorNo donationNot procuredNo donationBhutanMixedNo donationNot procuredNo donationNot procuredNo donationNot procuredNo donationNot procuredNo donationIndiaMixedNo donationCentralizedNo donationNot procuredNo donationNot procuredNo donationNot procuredNo donationMaldivesMixedNo donationCentralizedNo donationCentralizedNo donationCentralizedNo donationNot procuredNo donationMyanmarMixedNo donationNot procuredNo donationMixedNo donationNot procuredNo donationNot procuredNo donationNepalDecentralizedNo donationDecentralizedFHI 360 donation (2024)DecentralizedNo donationDecentralizedNo donationNot procuredNo donationSri LankaCentralizedNo donationCentralizedNo donationCentralizedNo donationCentralizedMedical Supply Division donation (2022)aCentralizedNo donationThailandMixed (hospital-based)No donationNot procuredNo donationNot procuredNo donationNot procuredNo donationNot procuredNo donationTimor-LesteCentralizedNo donationCentralizedWHO donation (2024)CentralizedWHO donation (2024)Not procuredNo donationCentralizedNo donationIU: international units; WHO: World Health Organization.a Medical Supply Division is a government organization responsible for providing pharmaceuticals. Procurement system and donation status of penicillin products, WHO South-East Asia, 2022–2024 IU: international units; WHO: World Health Organization. a Medical Supply Division is a government organization responsible for providing pharmaceuticals. Four of the reporting countries procure benzathine penicillin G 2.4 million IU through centralized systems. Nepal uses a decentralized approach and also received a donation from FHI 360 and WHO in 2024. Five countries procure penicillin G; four through centralized or mixed arrangements while Nepal relies on decentralized procurement. Timor-Leste received donations from WHO for benzathine penicillin G 2.4 million IU and penicillin G in 2024. Maldives and Sri Lanka procure penicillin V 250 mg through a centralized approach. Sri Lanka also reported a donation facilitated by the government’s Medical Supply Division in 2022. Penicillin V 500 mg has the least information, with confirmed centralized procurement only in Sri Lanka and Timor-Leste. India is planning decentralized procurement through state-level units, including state-acquired immunodeficiency syndrome control societies for procurement related to sexually transmitted infections. Product availability and shortages Table 6 presents data on product availability and shortages across Member States for the period 2022–2024. Benzathine penicillin G 1.2 million IU was consistently available in Myanmar and Sri Lanka; the Maldives and Thailand reported shortages related to meeting routine programmatic demand, as reflected in country stock and supply; Timor-Leste reported delays and four countries did not report on stockout. Benzathine penicillin G 2.4 million IU was sufficient in Sri Lanka; five countries reported shortages while three countries did not report. Most countries (6/9) did not report on the stockout of penicillin G and only Myanmar reported adequate procurement. Penicillin V 250 mg was sufficient only in Sri Lanka, although an interruption occurred during 2022 due to economic crisis and five countries did not report. For penicillin V 500 mg, data were limited; only Thailand and Timor-Leste reported supply and both indicated inadequate supply. Table 6Availability and shortages of penicillin formulations, WHO South-East Asia Region, 2022–2024Member StateBenzathine penicillin G 1.2 million IUBenzathine penicillin G 2.4 million IUPenicillin GPenicillin V 250 mgPenicillin V 500 mgProcurement adequacyStock-out (shortage)Procurement adequacyStock-out (shortage)Procurement adequacyStock-out (shortage)Procurement adequacyStock-out (shortage)Procurement adequacyStock-out (shortage)BangladeshNRNRNRNoNRNRNRNRNRNRBhutanNRNRNoNoNRNRNoNoNRNRIndiaNRNRNoNoNRNRNRNRNRNRMaldivesNoYesNoYesNRNRNRNRNRNRMyanmarYesYes a NRNRYesNRNRNRNRNRNepalNRNoNRNRNRNRNRNoNRNRSri LankaYesNoYesNoNRNRYesYes b NRNRThailandNo c YesNoNoNoNoNoNoNoNoTimor-LesteNoYesNoYesNoYesNoYesNoYesIU: international units; NR: not reported; WHO: World Health Organization.a Due to 3 months shipment delay.b Due to economic crisis.c Due to limited local manufacturers. Availability and shortages of penicillin formulations, WHO South-East Asia Region, 2022–2024 IU: international units; NR: not reported; WHO: World Health Organization. a Due to 3 months shipment delay. b Due to economic crisis. c Due to limited local manufacturers. Clinical indications and use guidelines We identified national guidance on the clinical use of penicillin across the nine Member States. Most countries include benzathine penicillin G for the treatment of syphilis and rheumatic heart disease, with additional indications, such as yaws, in some settings. Bangladesh, India, Myanmar, Nepal, Sri Lanka and Thailand have guidelines for benzathine penicillin G 1.2 million IU and Maldives reference it in broader guidance for sexually transmitted infections. Formal guidelines are absent in Bhutan and Timor-Leste. Guidance for benzathine penicillin G 2.4 million IU is available in India, Myanmar, Nepal and Thailand, with partial coverage in Maldives. Treatment guidelines in India, Myanmar and Sri Lanka cover penicillin G; five countries cover penicillin V 250 mg and no country reported having guidelines for the 500 mg formulation. Clinical indications also vary by country (Table 7). India, Nepal and Sri Lanka report the broadest range of penicillin uses across multiple conditions and populations, while Maldives and Myanmar focus primarily on syphilis and rheumatic heart disease. Bhutan and Timor-Leste do not specify indications or patient groups for penicillin formulations. (Table 7). Table 7Clinical indications and inclusion in the national guidelines for penicillin formulations, WHO South-East Asia Region, 2025Product CountryIncluded in national guidelinesIndicationBenzathine penicillin G 1.2 million IUBangladeshYesAcute otitis media; group A streptococcal infections; syphilis; diphtheria carrier prophylaxis; streptococcal impetigo; primary and secondary prophylaxis of rheumatic feverIndiaYesSyphilis; endemic treponematoses (yaws, bejel, pinta); streptococcal infections; primary and secondary prophylaxis of rheumatic fever and rheumatic heart disease (standard prophylactic dose, age- and weight-adjusted)MaldivesPartiallySyphilisMyanmarYesSyphilis, rheumatic heart disease (secondary prophylaxis)NepalYesSyphilis, erysipelas; yaws; pinta; rheumatic fever; post-streptococcal glomerulonephritisSri LankaYesSyphilis, limited use for streptococcal infections and prophylaxis (systemic infections primarily managed with aqueous penicillin G)Benzathine penicillin G 2.4 million IUIndiaYesSyphilis (adult treatment dosing); endemic treponematoses; selected streptococcal infections (not routinely used for rheumatic heart disease prophylaxis)Penicillin G 1 million IUIndiaYesNeurosyphilis; congenital syphilis; oto-syphilis; ocular syphilisMyanmarYesCongenital syphilisSri LankaYesSevere systemic infections including meningitis, endocarditis, and anthraxPenicillin V 250 mgBangladeshYesRheumatic heart fever (alternative prophylaxis to benzathine penicillin G)IndiaYesRheumatic heart disease (alternative prophylaxis)MyanmarYesRheumatic heart disease (alternative prophylaxis)NepalYesAcute otitis media; rheumatic feverSri LankaYesSevere systemic infections including meningitis and endocarditis (limited use)IU: international units; WHO: World Health Organization. Clinical indications and inclusion in the national guidelines for penicillin formulations, WHO South-East Asia Region, 2025 IU: international units; WHO: World Health Organization. Costs As of 2025, benzathine penicillin G 1.2 million IU ranged from approximately 0.15 United States dollars (US$) in Bangladesh to US$ 1.84 in Thailand and US$ 3.45 in Timor-Leste. The 2.4 million IU formulation showed a similar pattern, with lower prices per vial in Bangladesh and Bhutan and higher prices in India (US$ 0.82) and Timor-Leste (US$ 4.10; Fig. 1). Unit cost comparison of benzathine penicillin G, WHO South-East Asia Region, 2025 US$: United States dollars; WHO: World Health Organization. Note: the figure shows the unit costs for those countries that report cost data. Bangladesh, India, Sri Lanka and Thailand reported penicillin G prices; unit costs were similar at US$ 0.56–0.59 (Fig. 2). Penicillin V 250 mg was widely available, with prices at around US$ 0.02 per tablet reported in four countries, although Myanmar reported a higher price (US$ 0.12; Fig. 3). Penicillin V 500 mg has limited pricing data; only Bangladesh provided data (Fig. 3). Unit cost comparison of penicillin G, WHO South-East Asia Region, 2025 US$: United States dollars; WHO: World Health Organization. Note: the figure shows the unit costs for those countries that report cost data. Unit cost comparison of penicillin V, WHO South-East Asia Region, 2025 US$: United States dollars; WHO: World Health Organization. Note: the figure shows the unit costs for those countries that report cost data. Quantification of demand and surveillance mechanisms For 2025, quantification approaches and demand reporting varied considerably across countries and penicillin formulations, with a limited number of countries conducting formal estimation and surveillance. Where implemented, countries use a mix of facility-level reporting, programme data and consumption-level approaches. Reported annual demand varied widely, from very low volumes (25 vials of benzathine penicillin G 1.2 million IU) in Maldives to substantial requirements, including up to around 100 000 vials of benzathine penicillin G 1.2 million IU and approximately 732 000 vials of benzathine penicillin G 2.4 million IU in Sri Lanka. Quantification of penicillin G and penicillin V remained limited. Timor-Leste reported an annual need of approximately 2790 vials of penicillin G and 192 500 tablets of penicillin V 250 mg and Sri Lanka indicated they need approximately 15 million tablets of penicillin V 250 mg. No countries reported systems for quantifying penicillin V 500 mg. Surveillance systems are inconsistently applied, with structured approaches reported only in Bhutan, Myanmar and Timor-Leste. Demand forecasting based on disease burden data Morbidity-based forecasting estimated the total demand for penicillin-based treatments at 7485 vials of penicillin G; approximately 171 966 061 vials of benzathine penicillin G 2.4 million IU for syphilis and rheumatic heart disease; and 923 million tablets of penicillin V 250 mg. These totals reflect adult demand only; we have not included demand estimates for paediatric rheumatic heart disease. The corresponding costs are US$ 13 841, US$ 12 703 and US$ 48 005 181, respectively. India leads in demand (and total annual cost burden) for benzathine penicillin G 2.4 million IU. India also has the highest demand for penicillin V 250 mg, while Bangladesh and Thailand incur the highest total annual cost for it. Detailed estimates are provided in Table 8. Table 8Morbidity-based forecasting of penicillin demand and total costs, WHO South-East Asia Region, 2025Member StateDemandCost, US$Penicillin G vialsaBenzathine penicillin G 2.4 million IU vialsbBenzathine penicillin G 2.4 million IU vialscPenicillin V 250 mg, tabletsdPenicillin GaBenzathine penicillin G 2.4 million IU vialsbBenzathine penicillin 2.4 million IU vialscPenicillin V 250 mgdBangladesh0017 621 12994 584 003003 348 01525 064 761Bhutan24522278 410420 87604917 2500India72025 640135 116 410725 257 199011 02558 100 0560Maldives0054 710293 6620016 4130Myanmar06 9976 343 22734 048 2020000Nepal702 0112 796 68215 01 60470.56000Sri Lanka6 450287196 6301 055 4426849.9000591 047Thailand015 5377 057 15037 880 29300022 349 373Timor-Leste0374148 234795 6686920.461629645 7070Total7 48551 068171 966 061923 053 12113 84112 70362 127 44148 005 181IU: international unit; US$: United States dollars; WHO: World Health Organization. a Indicates demand and costs of benzathine penicillin G for congenital syphilisb Indicates demand and costs for pregnant women with syphilisc Indicates demand and costs for pregnant women with syphilis and adult rheumatic heart diseased Indicates demand and costs for adult rheumatic heart diseaseNotes: WHO treatment guidelines for syphilis and rheumatic heart disease were used to estimate the demand forecasts.1,2 Penicillin V 500 mg was not estimated due to the lack of data provided by the countries. Morbidity-based forecasting of penicillin demand and total costs, WHO South-East Asia Region, 2025 IU: international unit; US$: United States dollars; WHO: World Health Organization. a Indicates demand and costs of benzathine penicillin G for congenital syphilis b Indicates demand and costs for pregnant women with syphilis c Indicates demand and costs for pregnant women with syphilis and adult rheumatic heart disease d Indicates demand and costs for adult rheumatic heart disease Notes: WHO treatment guidelines for syphilis and rheumatic heart disease were used to estimate the demand forecasts.1,2 Penicillin V 500 mg was not estimated due to the lack of data provided by the countries. Discussion Access to benzathine penicillin G formulations across the South-East Asia Region remains uneven, with gaps in registration, manufacturing, procurement and clinical use. This study identifies three interrelated challenges, including wide price variation across countries, inconsistent national clinical guidance and persistent supply insecurity which is linked to a highly concentrated global manufacturing base. We found that essential formulations, including benzathine penicillin G, penicillin G and penicillin V remain vulnerable to supply disruption despite their inclusion in the WHO Model list of essential medicines, 24th list.5 Prices vary substantially across the region, reflecting fragmented procurement systems, limited supplier competition and small-volume markets. These findings are consistent with evidence that penicillin supply insecurity is driven by market consolidation,6,21 environmental compliance requirements and low commercial incentives,22 with only one WHO-prequalified finished-product manufacturer as of 2025.23 Furthermore, our analysis shows that regional demand for penicillin is substantially higher than previously estimated, particularly when the needs for syphilis and rheumatic heart disease are considered together. Our morbidity-based estimates, indicating that approximately 172 million vials of benzathine penicillin G 2.4 million IU are required annually across the South-East Asia Region, far exceed earlier global and regional estimates and are constrained by limited country coverage and reliance on historical procurement data.24,25 Notably, previous analyses from the region were largely limited to India.26 Also, we observed substantial variation in national guidelines and surveillance practices, highlighting inconsistencies in programme implementation. These findings align with previous reports highlighting implementation barriers, including variability in clinical guidance and delivery practices27 and with evidence that benzathine penicillin G is underused in antenatal care, in part due to limited provider confidence in administering injections.28 WHO recommends prioritizing essential penicillin formulations during shortages, improving forecasting and supporting manufacturers to maintain supply.1 However, prescribing patterns are shifting towards alternative therapies due to prescriber preferences and safety concerns, even though there are no clinically equivalent substitutes for first-line treatment of syphilis and rheumatic heart disease.29,30 Gaps in guidance and procurement further affect specific formulations. Penicillin G is frequently excluded from national guidelines and is used inconsistently across countries. Similarly, penicillin V 500 mg lacks structured quantification and monitoring systems in all countries, indicating limited data availability and weak oversight for this formulation. Small-volume markets such as Maldives and Timor-Leste face barriers including minimum order quantities, long lead times and high per-unit costs driven by dependence on imports. In India and Nepal, penicillin prices vary by procurement modality, with centralized purchasing generally securing lower prices than decentralized procurement because of greater competition.31 Despite subsidies, patients often still incur substantial out-of-pocket costs for administration and transport.32 Data gaps persist, particularly in paediatric rheumatic heart disease dosing and penicillin V 500 mg, and few countries estimate treatment needs for maternal syphilis. Our analysis is limited by its focus on public-sector systems, the exclusion of private-sector dynamics and medicine quality and reliance on procurement prices without adjustments for inflation or purchasing power. We based demand estimates on age-standardized prevalence; therefore, the underlying rheumatic heart disease and syphilis burden data may be underestimated. In addition, there were reporting gaps across responding countries and despite verification of non-responses we did not impute these. These shortcomings limited the available information on procurement systems and medicine availability and shortages in several countries. Nevertheless, our findings highlight the scale of regional penicillin need and the urgency of targeted procurement action amid ongoing shortages and a shrinking manufacturer base. In conclusion, the persistent gaps in registration, procurement, pricing and guidelines undermine access to essential penicillin formulations across the South-East Asia Region. Price disparities, supply shortages and weak forecasting reflect structural market failures driven by fragmented procurement systems, limited supplier competition and insufficient policy prioritization. Addressing these challenges will require stronger procurement systems, harmonized regulatory frameworks and coordinated support for sustainable manufacturing. Regional collaboration and targeted policy action are essential to ensuring equitable access to penicillin and reducing the burden of two treatable yet persistently neglected conditions in the region. Competing interests: None declared. References